METHODS: This was a retrospective analysis of the U.S. Scientific Registry of Transplant Recipients data from 2006 to August 2022 in adult recipients. Patients were excluded if they were multiorgan transplant, re-do transplants, or less than 1 year post transplant.
RESULTS: Recipients ≥70 had a 1-year survival of 87.5%, compared to 91.1% for <60%, and 88.4% for 60-69 years (p < 0.001). Survival improved numerically, but not significantly, as transplant eras progressed for those ≥70 years. Survival by Kaplan-Meier analysis was greatest at 5 years for <60 years (80.6%), compared to 60-69 years (78.2%) and ≥70 years (77.1%). When comparing 60-69 years to ≥70 years by this same metric, there was significant difference (p = 0.12). One year survival for those ≥70 years has improved from 2000-2009 (80.7%) to 88.5% since October 2018 (p < 0.001). As recipients increased in age, they were more likely to be male, and less likely to be Black or Hispanic/Latino (p < 0.001).
CONCLUSIONS: Overall, HT outcomes are excellent for carefully selected patients ≥70 years, and transplanting patients in this age cohort can be considered.
方法:这是对2006年至2022年8月美国移植接受者科学注册数据的回顾性分析。如果是多器官移植的患者被排除在外,重新移植,或移植后不到1年。
结果:70岁以上的患者一年生存率为87.5%,<60岁时为91.1%,60-69岁时为88.4%(p<0.001)。存活率在数值上提高了,但并不重要,随着移植时代的进展,那些≥70年。通过Kaplan-Meier分析,在<60年的5年生存率最高(80.6%),60-69岁(78.2%)和≥70岁(77.1%)。当用相同的度量比较60-69年与70年以上时,差异有统计学意义(p=0.12)。70岁以上人群的一年生存率从2000-2009年(80.7%)提高到2018年10月以来的88.5%(p<0.001)。随着接受者年龄的增长,他们更有可能是男性,并且不太可能是黑人或西班牙裔/拉丁裔(p<0.001)。
结论:总体而言,对于精心选择的≥70岁的患者,HT结果非常好。和移植患者在这个年龄段可以考虑。